Literature DB >> 19464061

Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: a variability and diagnostic performance study.

Christopher Kai-Shun Leung1, Carol Yim-Lui Cheung, Robert N Weinreb, Quanliang Qiu, Shu Liu, Haitao Li, Guihua Xu, Ning Fan, Lina Huang, Chi-Pui Pang, Dennis Shun Chiu Lam.   

Abstract

OBJECTIVE: To evaluate and compare the retinal nerve fiber layer (RNFL) measurement variability, diagnostic sensitivity and specificity for glaucoma detection, and strength of the structure-function association obtained with a spectral-domain optical coherence tomography (OCT) device (Cirrus HD-OCT; Carl Zeiss Meditec, Inc., Dublin, CA) and a time-domain OCT device (Stratus OCT; Carl Zeiss Meditec, Inc.).
DESIGN: Prospective, cross-sectional study. PARTICIPANTS: Ninety-seven normal subjects and 83 glaucoma patients.
METHODS: One eye from each subject was imaged with Cirrus HD-OCT and Stratus OCT. Sixteen and 31 normal eyes were selected randomly to evaluate intravisit repeatability and intervisit reproducibility, respectively. The agreement of RNFL measurements was evaluated with Bland-Altman plots. The diagnostic sensitivity and specificity was examined with the area under the receiver operating characteristic curve (AUC). The association between average RNFL thickness and visual field sensitivity was evaluated with a second-order regression model. MAIN OUTCOME MEASURES: Retinal nerve fiber layer measurement variability, AUC, and coefficient of determination (R(2)).
RESULTS: The intravisit repeatability of Cirrus HD-OCT ranged between 5.12 and 15.02 mum, and the intervisit reproducibility ranged between 4.31 and 22.01 mum. The intervisit variabilities of sectoral and average RNFL thicknesses were lower in Cirrus HD-OCT compared with Stratus OCT with significant differences at 1, 3, 4, and 8 to 11 o'clock (P< or =0.021). There were proportional biases of RNFL measurements between the 2 OCT devices. The difference of RNFL thicknesses increased with the means. The average (AUC, 0.962 for Cirrus HD-OCT and 0.956 Stratus OCT), superior (AUC, 0.963 and 0.950, respectively), and inferior (AUC, 0.949 and 0.931, respectively) RNFL thicknesses demonstrated the greatest AUCs in both OCT devices with no significant difference detected between the respective measurements (P> or =0.120). The strength of the structure-function association was comparable between Cirrus HD-OCT (R(2) = 0.580) and Stratus OCT devices (R(2) = 0.623; P = 0.918).
CONCLUSIONS: Although the diagnostic performance and the strength of the structure-function association were comparable between Cirrus HD-OCT and Stratus OCT RNFL measurements, Cirrus HD-OCT demonstrated lower measurement variability compared with Stratus OCT with significant differences at 1, 3, 4, and 8 to 11 o'clock. The poor agreement was likely related to the different inherent characteristics of the 2 OCT systems.

Entities:  

Mesh:

Year:  2009        PMID: 19464061     DOI: 10.1016/j.ophtha.2009.04.013

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  171 in total

1.  Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function.

Authors:  Robert N Weinreb; Paul L Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-04       Impact factor: 4.799

2.  Effect of signal strength on reproducibility of peripapillary retinal nerve fiber layer thickness measurement and its classification by time-domain optical coherence tomography.

Authors:  Eun Suk Lee; Hyunjoong Kim; Joon Mo Kim
Journal:  Jpn J Ophthalmol       Date:  2010-11-05       Impact factor: 2.447

3.  Reproducibility and agreement in evaluating retinal nerve fibre layer thickness between Stratus and Spectralis OCT.

Authors:  S N Arthur; S D Smith; M M Wright; A L Grajewski; Q Wang; J M Terry; M S Lee
Journal:  Eye (Lond)       Date:  2010-11-26       Impact factor: 3.775

4.  Structure-function relationships using the Cirrus spectral domain optical coherence tomograph and standard automated perimetry.

Authors:  Mauro T Leite; Linda M Zangwill; Robert N Weinreb; Harsha L Rao; Luciana M Alencar; Felipe A Medeiros
Journal:  J Glaucoma       Date:  2012-01       Impact factor: 2.503

5.  Neuroretinal alterations in the early stages of diabetic retinopathy in patients with type 2 diabetes mellitus.

Authors:  P Carpineto; L Toto; R Aloia; V Ciciarelli; E Borrelli; E Vitacolonna; M Di Nicola; L Di Antonio; R Mastropasqua
Journal:  Eye (Lond)       Date:  2016-02-12       Impact factor: 3.775

6.  Comparison of retinal nerve fiber layer measured by time domain and spectral domain optical coherence tomography in optic neuritis.

Authors:  G Rebolleda; A García-García; H R Won Kim; F J Muñoz-Negrete
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

Review 7.  Imaging of the retinal nerve fibre layer with spectral domain optical coherence tomography for glaucoma diagnosis.

Authors:  Kyung Rim Sung; Jong S Kim; Gadi Wollstein; Lindsey Folio; Michael S Kook; Joel S Schuman
Journal:  Br J Ophthalmol       Date:  2010-10-28       Impact factor: 4.638

8.  Effect of disease severity on the performance of Cirrus spectral-domain OCT for glaucoma diagnosis.

Authors:  Mauro T Leite; Linda M Zangwill; Robert N Weinreb; Harsha L Rao; Luciana M Alencar; Pamela A Sample; Felipe A Medeiros
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-24       Impact factor: 4.799

9.  Rates of Retinal Nerve Fiber Layer Loss in Contralateral Eyes of Glaucoma Patients with Unilateral Progression by Conventional Methods.

Authors:  Ting Liu; Andrew J Tatham; Carolina P B Gracitelli; Linda M Zangwill; Robert N Weinreb; Felipe A Medeiros
Journal:  Ophthalmology       Date:  2015-09-15       Impact factor: 12.079

10.  Diagnostic specificities of retinal nerve fiber layer, optic nerve head, and macular ganglion cell-inner plexiform layer measurements in myopic eyes.

Authors:  Ahmad A Aref; Fouad E Sayyad; Jean-Claude Mwanza; William J Feuer; Donald L Budenz
Journal:  J Glaucoma       Date:  2014 Oct-Nov       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.